The Deal Machine: Understanding M&A in Beauty and Wellness

Fifteen years of proprietary transaction data reveal a sector defined by structural resilience, counter-cyclical deal logic, and a consolidation dynamic that no public source has yet been able to map in full.

EXECUTIVE SUMMARY

Our proprietary database, covering nearly 1,300 full buyout and majority investment transactions from 2010 to the present, establishes what no public source can: a granular, longitudinal picture of M&A dynamics across every major category in beauty and wellness. The data reveal a sector that has compounded deal volume at pace, demonstrated a structural resistance to macro and trading downturns that sets it apart from most consumer categories, and evolved its areas of strategic focus in ways that illuminate where capital sees the most durable value.

WHY BEAUTY M&A COMMANDS ATTENTION

Beauty and wellness occupies a unique position among consumer sectors. Its underlying demand is non-cyclical in nature, driven by behavioral habits and self-care routines that consumers protect even as discretionary budgets compress. This characteristic, more commonly described as the lipstick effect but operating at far greater structural depth, has historically translated into premium M&A multiples and attracted a broadening universe of acquirers: from strategic conglomerates to private equity firms, family offices, and crossover investors from adjacent sectors including health, pharma, and food.

The sector has also benefited from the convergence of beauty and wellness as consumer categories. Products that once sat in clearly distinct aisles, ingestible supplements, topical skincare, haircare, and color cosmetics, increasingly address common consumer goals around longevity, skin health, and self-expression. This convergence has widened the acquisition perimeter for many strategic buyers and created new entry points for financial sponsors seeking category-level platforms.

M&A in this space is further animated by the particular economics of beauty brands. The combination of high gross margins, strong consumer loyalty, and relatively low capital intensity creates a financial profile that lends itself to roll-up strategies and leveraged acquisition structures alike. When a brand reaches a certain size, its economics become difficult to replicate organically; acquisition is frequently the more efficient growth path for larger players.

THE CARRARA ADVISORY DATABASE: SCOPE AND METHODOLOGY

Our proprietary transaction database currently holds close to 1,300 individual deals, encompassing full buyouts and majority investments across the beauty and wellness landscape. Coverage extends from 2010 to the present, giving the dataset a time span sufficient to capture multiple market cycles, the rise and partial correction of direct-to-consumer brands, the acceleration of wellness into the mainstream, and the evolution of manufacturing and supply chain as strategic assets.

The database covers nine primary categories: Skincare and Personal Care, Makeup, Fragrances, Haircare, Beauty Manufacturing and Suppliers, Nutraceuticals, Nutricosmetics, Beauty Retail, and Others (which includes digital platforms, apps, and services that do not fall within the above). Categories such as Beauty Retail, Manufacturing and Suppliers, Nutraceuticals, and Nutricosmetics were tracked separately only from approximately 2023 onward; transactions in these categories prior to that date are included within Others in earlier periods. This tracking evolution reflects the growing strategic relevance of those sub-segments, not a discontinuity in deal activity.

The dataset is limited to full buyouts and majority investments. Minority stakes, licensing deals, joint ventures, and earn-out structures without majority transfer are excluded. This boundary ensures that the transactions captured represent genuine changes of control, where an acquirer is making a commitment to own and operate the asset, and where meaningful valuation and structural information is typically available.

With nearly 1,300 transactions recorded over fifteen years, the CARRARA Advisory database is among the most comprehensive proprietary datasets on beauty and wellness M&A available to practitioners today.

VOLUME THROUGH TIME: A FIFTEEN-YEAR ARC

Transaction volume in the dataset grew from a modest base of fewer than 25 deals per year in the early 2010s to a sustained run rate above 75 deals annually from 2018 onward, reaching a peak of 95 transactions in 2019 and 96 in 2023. Exhibit 1 captures the Q1 (January through March) trajectory across all seventeen years tracked, offering a consistent seasonal window to observe structural momentum independent of year-end closing patterns.

Exhibit 1: Transaction volume, Q1 (January–March) by year and category. Beauty Retail, Manufacturing/Suppliers, Nutraceuticals, and Nutricosmetics were tracked as separate categories only from approximately 2023; prior transactions in these categories are included within Others.

The Q1 trajectory tells a story of compounding deal activity with two distinct acceleration phases. The first, from roughly 4 deals in Q1 2010 to 20 in Q1 2019, reflected the organic growth of the acquirer universe and the maturation of beauty as a private equity asset class. The second phase, visible from 2022 onward, was characterized by a structural expansion of the target universe as manufacturing, supply chain, and wellness sub-categories emerged as investable segments in their own right. Q1 2024 and Q1 2025, at 29 and 33 transactions respectively, confirm that this expanded universe has sustained deal pace well above the levels that characterized the pre-2018 market.

Q1 2026, at 15 transactions, sits below the prior two comparable periods but remains above the levels that defined the first half of the dataset. As discussed in the macro section below, this moderation is consistent with a financing environment that remains tighter than the 2021 to 2023 peak period, and with the broader measured pace of deal-making observed across consumer sectors in the current context. It does not represent a structural retreat.

Exhibit 2: Full-year transaction volume by year and category (2026 reflects Q1 only). * Others includes digital platforms, apps, and services, as well as Beauty Retail and Nutricosmetics for years prior to 2023 when those categories were not tracked separately. † Full-year totals reflect the master transaction count and may differ from the sum of category columns due to deals not yet assigned to a specific category at time of publication.

THE MACRO RELATIONSHIP: DEAL VOLUME, BEAUTY GROWTH, AND GDP

One of the most analytically valuable outputs of a dataset spanning fifteen years is the ability to examine how M&A activity in beauty correlates, or does not correlate, with the macro and sector-level growth environment. Exhibit 3 sets the full-year transaction count against annual beauty industry revenue growth and global GDP growth for each year in the dataset. The findings are counter-intuitive in important ways and carry direct implications for how investors and operators should read the current environment.

M&A Volume Does Not Follow Beauty Revenue

The most fundamental observation from Exhibit 3 is that deal volume and beauty revenue growth are largely uncorrelated on an annual basis. Beauty revenue grew at 4 to 6 percent annually between 2014 and 2019, and deal volume grew broadly in parallel over that period. But in 2020, when beauty revenue contracted 8 percent in one of the worst years in the sector's recent history, deal volume fell only from 95 to 87, a decline of just over 8 percent against a revenue decline ten times that magnitude. More strikingly, in 2025, when beauty growth turned negative at -0.6 percent against a backdrop of positive 3.4 percent global GDP growth, deal volume actually held at 78 transactions, virtually flat with 77 in 2024 and meaningfully above the 75 recorded in the strong-growth year of 2021.

Exhibit 3: Annual transaction volume versus beauty industry revenue growth and global GDP growth. The Deals / Beauty Growth Point ratio is calculated as total transactions divided by the beauty YoY growth rate in percentage points; n/m indicates not meaningful due to negative beauty growth. Beauty growth figures are global industry estimates; GDP growth figures are IMF World Economic Outlook data.

This resilience reflects a structural feature of how M&A logic operates in beauty. Strategic buyers and financial sponsors are not acquiring trailing revenue; they are acquiring forward positioning, brand equity, consumer relationships, and supply chain capabilities. A period of sector-level revenue softness, particularly one driven by idiosyncratic factors such as China demand deceleration or tariff headwinds rather than structural demand erosion, frequently creates more attractive entry points rather than fewer. Sellers who might otherwise hold out for peak-cycle multiples become more flexible. Distressed situations that were invisible during the growth phase begin to surface.

In 2025, beauty revenue turned negative for the first time in the dataset's history outside of a macro recession, while deal volume held at 78 transactions, essentially flat with 2024. This is not coincidence. It is the structural logic of a sector where M&A is driven by consolidation necessity and forward positioning, not by trailing growth rates.

The 2021 Paradox: When the Best Macro Year Produced Fewer Deals

The most striking single-year anomaly in the dataset is 2021. Global GDP grew 6.2 percent, its strongest performance across all years tracked. Beauty revenues rebounded 8 percent following the 2020 contraction. By any conventional reading of deal-making conditions, 2021 should have been a peak year for transaction volume. Instead, it produced only 75 deals, fewer than 2019, 2020, 2022, 2023, 2024, or 2025. The explanation is structural rather than cyclical: 2021 was a year of financing recalibration following the COVID shock, during which deal processes that were paused or restructured in 2020 were still working their way through to resolution, and new processes had not yet reached closing. The subsequent recovery to 80 in 2022 and 96 in 2023 confirms that the 2021 figure was a timing artifact, not a signal about strategic intent.

The implication for practitioners is important: do not read a single-year dip in deal volume as evidence of strategic disengagement. The pipeline that builds during a slow year frequently delivers in the subsequent one or two years, and the current Q1 2026 pace should be interpreted with that historical pattern firmly in mind.

The 2025 Decoupling Is Historically Unique

2025 represents a configuration that does not appear elsewhere in the dataset. It is the only year in which beauty revenues declined while the broader economy grew. Every other instance of sector-level revenue softness in the data, and there is only one comparable year, 2020, was accompanied by a global recession. The 2025 outcome was driven by a specific and well-documented set of factors: the continued deceleration of Chinese consumer demand following the post-COVID rebound, a persistent currency headwind for globally reporting companies, and the early-year impact of U.S. tariff escalation as detailed in CARRARA Advisory's March 2026 analysis of the sector's tariff exposure. These are real pressures, but they are not evidence of structural demand deterioration. The underlying consumer habit of spending on beauty remains intact; what shifted was the macro and geopolitical context in which that spending occurred.

For deal-makers, the 2025 configuration is instructive precisely because of its uniqueness. It confirms that the beauty consumer is more resilient than the beauty company in a complex operating environment, and that acquirers who can see through near-term noise to the underlying brand and consumer asset are operating with a structural advantage over those who anchor to trailing financials.

Deal Intensity and the Question of Market Saturation

The ratio of annual deal count to beauty growth points, shown in the final column of Exhibit 3, captures how many transactions the market generates per percentage point of sector growth. This ratio rose from roughly 4 to 5 transactions per growth point in the early 2010s to a range of 14 to 17 from 2015 onward, peaking at 17.1 times in 2024. The increase reflects the growing number of financial buyers active in the space and the broadening of the target universe as new sub-categories emerged as investable assets.

What the ratio also reveals is that the absolute annual ceiling of the dataset, 96 transactions in 2023, has been approached but never materially exceeded. This raises a legitimate question about available target supply in traditional categories. The universe of independent, majority-acquirable beauty brands at meaningful scale is finite, and the compositional shift toward manufacturing, supply chain, and wellness visible in the most recent years is in part a response to this dynamic: as the classic brand acquisition opportunity set matures, capital is finding new expressions of the same underlying investment thesis.

CATEGORY DYNAMICS: WHERE CAPITAL HAS MOVED

The full-year data in Exhibit 2 makes visible a set of structural shifts in category preference that run beneath the aggregate volume trend and carry significant strategic implications.

Skincare Remains the Anchor

Skincare and Personal Care has been the single largest category by deal count in virtually every year of the dataset, typically accounting for 30 to 45 percent of annual transaction volume. Its dominance reflects structural advantages: high average selling prices, strong brand equity potential, a product development cycle that enables premium positioning through ingredient storytelling, and consumer engagement driven by growing skin health awareness. The category posted 27 full-year transactions in both 2024 and 2025, and 7 in Q1 2026 alone, confirming an undiminished pace of activity even as aggregate volumes have moderated from the 2023 peak of 41 skincare deals.

Makeup: A Category in Structural Deceleration

Makeup, once a leading category in terms of acquisition targets with 18 transactions in 2018, has experienced a pronounced deceleration. Deal volume compressed to 5 full-year transactions in 2024, 3 in 2025, and none in Q1 2026. This shift reflects increasing concentration among a smaller number of scaled platforms, a challenging organic growth environment for mass color cosmetics, and the growing premium that buyers assign to categories with clinical or health-adjacent positioning. Future deal activity in makeup is more likely to involve divisional carve-outs or portfolio rationalization by large conglomerates than independent brand acquisitions.

Fragrances: Sustained Strategic Interest with Cyclical Variation

Fragrance has maintained a consistent presence in the deal landscape, typically contributing between 5 and 17 transactions per year through the dataset. The 2024 dip to just 1 full-year transaction was anomalous; Q1 2026 has already recorded 2 fragrance deals and the full-year figure of 4 in 2025 suggests the category returned to its historical baseline. The segment benefits from high consumer willingness to pay, strong licensing leverage for acquirers with established luxury distribution, and the ongoing premiumization of artisanal and niche fragrance as an M&A target category.

Manufacturing and Suppliers: The Supply Chain Shift

The most significant structural development in the recent dataset is the emergence of Beauty Manufacturing and Suppliers as a distinct and substantial deal category. Having contributed no tracked transactions prior to 2023, the category delivered 17 full-year deals in 2024 and 18 in 2025, making it the second-largest category by volume in both years. This reflects a strategic recognition among private equity and large strategics that control of the supply chain confers durable competitive advantage in a market where brand differentiation is increasingly difficult to sustain and supply chain reliability is mission-critical. Q1 2026, with 4 manufacturing deals and an annualized pace above 15, confirms this is a structural rather than episodic trend.

Supplements and Nutraceuticals: The Wellness Bridge

Supplementation and nutraceuticals represent the clearest evidence of the beauty-wellness convergence in M&A terms. The category contributed 14 full-year transactions in 2024, its strongest year on record, before moderating to 4 in 2025. Q1 2026, at 3 deals, suggests a pace that, if sustained, would deliver a full-year count consistent with recent levels. This category is expected to attract growing capital allocation as the nutricosmetics market expands and the clinical and regulatory evidence base around beauty-from-within products continues to develop.

Beauty Retail: An Emerging M&A Category

Beauty Retail appeared as a distinct tracked category for the first time in 2025, contributing 7 full-year transactions and 1 deal in Q1 2026. Its emergence reflects two converging dynamics: the strategic value of owned retail as a direct consumer touchpoint, and the growing interest from financial buyers in multi-brand retail platforms that aggregate consumer traffic and purchasing data at scale. This is a category to monitor as consolidation in specialty beauty retail accelerates globally.

Q1 2026: EARLY SIGNALS IN A MEASURED MARKET

The first quarter of 2026 produced 15 transactions across the database. Skincare and Personal Care led with 5 deals, consistent with its structural dominance. Beauty Manufacturing contributed 4 transactions, continuing the supply chain investment thesis at a pace that, if maintained, would deliver one of its strongest full-year performances yet. Fragrances posted 2 deals, already double the full-year 2024 total. Haircare added 2 deals, and Beauty Retail made its first Q1 appearance with 1 transaction. Makeup recorded no transactions for the second consecutive Q1.

Extrapolating from Q1 pace alone, and recognizing that beauty M&A has historically exhibited second-half weighting due to year-end closing dynamics and the concentration of process launches in spring and autumn, a full-year 2026 count in the range of 60 to 70 transactions appears plausible under current conditions. The outcome will depend substantially on whether the financing environment and geopolitical backdrop, including ongoing uncertainty around the Gulf conflict that emerged in early 2026, provide conditions conducive to deal closing in the second half of the year.

Q1 2026's composition, led by skincare and manufacturing with notable fragrance activity and a complete absence of makeup, reflects a market that has internalized the category hierarchy. Capital is flowing to where clinical positioning, supply chain control, and scarcity of available assets intersect. That is not weakness; it is precision.

KEY TAKEAWAYS FOR PRACTITIONERS

Drawing on fifteen years of transaction data and the macro overlay provided by Exhibit 3, several durable conclusions emerge for operators, investors, and advisors active in beauty and wellness M&A.

The sector's M&A activity is structurally elevated and counter-cyclical. Deal volume in beauty does not follow revenue growth or macro conditions with any meaningful consistency. In both 2020 and 2025, years when the beauty industry faced severe revenue headwinds, deal volume proved remarkably resilient. Practitioners who pause activity during soft-revenue periods are likely surrendering entry-point advantage to those who do not.

Skincare is not a temporary preference. Its dominance across fifteen years of data, accounting for roughly a third of all transactions in most years and never relinquishing its leadership position, is a function of fundamental economic characteristics. Acquirers seeking platform-level assets in beauty should expect to pay accordingly, and should plan for the category to remain competitive for available assets.

Supply chain is the new brand equity. The rise of manufacturing and supplier transactions is one of the most significant structural shifts in the dataset. As the available universe of independent brand targets at scale becomes more constrained, capital is finding its expression upstream. This trend is likely to persist and potentially accelerate.

Wellness convergence is early-stage and high-conviction. Supplement and nutraceutical deals have moved from a rounding error to a structurally present category within a few years. With 14 full-year transactions in 2024 and continued activity in 2025 and Q1 2026, the category represents one of the highest-conviction growth areas for capital deployment over the next three to five years.

2025's negative beauty growth is idiosyncratic, not structural. It is the only instance in fifteen years of sector revenue declining while the broader economy grew, and it produced no retreat in deal volume. Its causes are well-documented and largely exogenous to the underlying consumer demand dynamic. Anchoring valuation assumptions or deal timelines to 2025 trading conditions risks producing material errors in both directions.

Volume cycles matter less than composition. The relevant question in any given year is not how many deals are closing, but which categories are attracting capital, at what prices, and on what strategic rationale. The answer to the price question, the multiples that the market has been paying across categories and across cycles, is the subject of the next issue in this series.

COMING NEXT  |  ISSUE 2

What Does Beauty Actually Cost?

In the next issue of this series, we turn to the question that every buyer, seller, and board member eventually asks: what multiple is the market actually paying? Drawing on the same proprietary database, we will publish transaction multiples on both revenue and EBITDA across deal years and categories, with trend analysis that reveals how valuations have moved across cycles, where the premium categories sit today, and what the current environment suggests about where multiples are heading. Skincare has commanded a sustained valuation premium, but by how much relative to haircare, fragrance, or manufacturing? The data, presented in this form for the first time, will provide a category-by-category answer.